On July 24, Stryker rose 3.04% in regular trading, trading at $319.29/share, with turnover of $580 million.

On the news front, Stryker is scheduled to report Q2 earnings on July 30 after market close. Consensus estimates project quarterly revenue of approximately $6.58 billion, representing a 10.95% year-over-year increase, while adjusted earnings per share are expected at $3.49, up 13.67% from the prior year. EBIT is forecasted at $1.703 billion, reflecting 13.28% growth. The anticipated acceleration follows a softer Q1 that was impacted by a cybersecurity incident, during which revenue rose just 2.63% and adjusted EPS declined 8.45% year-over-year.

Additionally, the company recently announced the full commercial launch of its Mako RPS handheld robotic system for total knee arthroplasty in the United States, expanding the Mako platform beyond robotic-arm assisted surgery into a handheld format. This product line extension reinforces Stryker's competitive positioning in the orthopedic robotics market ahead of the earnings release.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)